Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bulevirtide→

Bulevirtide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2012558-47-1
Molecular formula
C248H355N65O72
Molecular weight
5399 g/mol
Drug class
Hepatitis D virus (HDV) entry inhibitormyristoylated pre-S1 lipopeptide
Mechanism of action
Binds the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, blocking entry of hepatitis B and D viruses into liver cells. It prevents new infection of hepatocytes but does not directly eliminate intracellular viral genomes.
Indications / reported uses
  • Treatment of chronic hepatitis D virus (HDV) infection in adults with compensated liver disease, with or without concomitant HBV infection, under the EU-authorised Hepcludex indication; use in combination with HBV management as directed by specialist product information

Sources: EMA EPAR — Hepcludex (bulevirtide) · EMA product information — Hepcludex · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bulevirtide Environmental Risk Assessment (ERA) (the Bulevirtide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.